Olpasiran significantly reduces apoB-associated oxidised phospholipids (OxPL-apoB), according to results of a pre-specified analysis of data from the Phase 2 OCEAN(a)-DOSE trial.
Other articles available on Lp(a) Forum
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
